Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Brexit White Paper Would Keep Medtech Regulatory System – And Testing Just Once – Intact

Executive Summary

It looks as if the EU medtech regulatory system could survive intact in the UK, given terms of the UK blueprint for its future relationship with the EU after separation. But a storm of controversy must be navigated first.

You may also be interested in...



BSI Gives Clients Until March 31 To Submit For Recertification Under EU Directives

In an urgent notice to clients, notified body BSI warns that time is running out to recertify against the current EU directives, as pressures mount for all notified bodies.

Restless Summer For Brexit Officials – Both Sides Of The EU Divide

UK Brexit officials have been making positive noises at last about the proposals in the hoped-for trade deal that the UK is seeking for the post-EU period after March 29, 2019. But experience shows that the only certainty in Brexit is uncertainty, meaning several busy weeks ahead for those hammering out a UK-EU trade deal.

Brexit: Will UK Now Stockpile Devices? And Is It Certain The Country Will Continue With MDR?

UK starts to discuss emergency measures around devices as no-deal Brexit concerns mount. But it is still looking like the UK will continue to implement the Medical Device Regulation, in the short-term at least. Will it be a different matter for the IVD Regulation?

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT122962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel